Rigel issues letter to doctors on fatal infection signal for Gavreto

seekingalpha10-25

Rigel Pharmaceuticals has issued a "Dear Healthcare Provider" letter related to a new safety signal associated with Gavreto (pralsetinib), its drug for a type of non-small cell lung cancer. The letter...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2478694788?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1421919863/image_1421919863.jpg","is_english":true,"pubTime":"2024-10-25 05:19","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2478694788","market":"fut","top_or_hot":-1,"title":"Rigel issues letter to doctors on fatal infection signal for Gavreto","media":"seekingalpha","content":"<div>\n<p>Rigel Pharmaceuticals has issued a \"Dear Healthcare Provider\" letter related to a new safety signal associated with Gavreto (pralsetinib), its drug for a type of non-small cell lung cancer. The letter...</p>\n\n<a href=\"https://seekingalpha.com/news/4202160-rigel-issues-letter-doctors-fatal-infection-signal-gavreto\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rigel issues letter to doctors on fatal infection signal for Gavreto</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRigel issues letter to doctors on fatal infection signal for Gavreto\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-25 05:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4202160-rigel-issues-letter-doctors-fatal-infection-signal-gavreto><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Rigel Pharmaceuticals has issued a \"Dear Healthcare Provider\" letter related to a new safety signal associated with Gavreto (pralsetinib), its drug for a type of non-small cell lung cancer. The letter...</p>\n\n<a href=\"https://seekingalpha.com/news/4202160-rigel-issues-letter-doctors-fatal-infection-signal-gavreto\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://seekingalpha.com/news/4202160-rigel-issues-letter-doctors-fatal-infection-signal-gavreto","article_id":"2478694788","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1421919863/image_1421919863.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2478694788","pubTimestamp":1729804762,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Rigel Pharmaceuticals has issued a \"Dear Healthcare Provider\" letter related to a new safety signal associated with Gavreto , its drug for a type of non-small cell lung cancer. The letter states that an ad hoc analysis of a phase 3 trial \"has demonstrated an imbalance regarding the risk of severe and fatal infection, including severe opportunistic infections, between the pralsetinib and [standard of care] arms.\"  The company noted that fatal adverse events were reported in 14 patients (13%) in the pralsetinib arm, compared to 5 patients  in the SOC arm. Fatal infections occurred in 5 patients  in the pralsetinib arm, and zero in the SOC arm.  Rigel says that doctors should monitor patients on the drug for signs and symptoms of infection.","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","RIGL":"Rigel Pharmaceuticals"},"translate_title":"里格尔就加夫雷托的致命感染信号向医生发出信函","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RIGL":0.9},"content_text":"Rigel Pharmaceuticals has issued a \"Dear Healthcare Provider\" letter related to a new safety signal associated with Gavreto (pralsetinib), its drug for a type of non-small cell lung cancer. The letter states that an ad hoc analysis of a phase 3 trial \"has demonstrated an imbalance regarding the risk of severe and fatal infection, including severe opportunistic infections, between the pralsetinib and [standard of care] arms.\"  The company noted that fatal adverse events were reported in 14 patients (13%) in the pralsetinib arm, compared to 5 patients (4.8%) in the SOC arm. Fatal infections occurred in 5 patients (4.6%) in the pralsetinib arm, and zero in the SOC arm.  Rigel says that doctors should monitor patients on the drug for signs and symptoms of infection.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2478694788"}